GlaxoSmithKline announced that the FDA has approved Lamictal XR (lamotrigine extended-release tablets) as a once-a-day add-on therapy for epilepsy patients ≥13 years of age with partial onset seizures. Lamictal XR was shown to have significantly reduced the frequency of partial seizures in patients during a 19-week study compared with placebo.
Lamictal XR extended-release tablets are enteric-coated and contain a modified release formulation in the center of the tablet. This allows a controlled release of the drug in the acidic environment of the stomach, leading to gradual release of lamotrigine into the bloodstream.
Lamictal XR is expected to be available in pharmacies this summer.
For more information call (888) 825-5249 or visit www.gsk.com.